{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:36:28Z","timestamp":1768037788169,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":2988,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Associazione per la lotta alla Sindrome Emolitico Uremica (SEU)"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1111\/jth.12615","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T02:28:48Z","timestamp":1400812128000},"page":"1440-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome"],"prefix":"10.1016","volume":"12","author":[{"given":"M.","family":"Cugno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gualtierotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Possenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Griffini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Grovetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Salardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cresseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Messa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ardissino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12615_bb0010","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12615_bb0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000337954","article-title":"Clinical grand rounds: atypical hemolytic uremic syndrome","volume":"35","author":"Hodgkins","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1111\/jth.12615_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/asheducation-2011.1.15","article-title":"Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations","volume":"2011","author":"Kavanagh","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.12615_bb0025","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","article-title":"Genetics and complement in atypical HUS","volume":"25","author":"Kavanagh","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/jth.12615_bb0030","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor\u00a0H autoantibodies block C\u2010terminal recognition function of factor\u00a0H in hemolytic uremic syndrome","volume":"110","author":"J\u00f3zsi","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12615_bb0035","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1055\/s-0030-1262887","article-title":"Transplantation in atypical hemolytic uremic syndrome","volume":"36","author":"Kavanagh","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.12615_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/jth.12615_bb0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12615_bb0050","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic\u2013uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12615_bb0055","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/jth.12615_bb0060","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic\u2013uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12615_bb0065","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome","volume":"26","author":"Weitz","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/jth.12615_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1681\/ASN.2010111145","article-title":"Targeting complement C5 in atypical hemolytic uremic syndrome","volume":"22","author":"Salant","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jth.12615_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical haemolytic uremic syndrome depends on complement C5","volume":"22","author":"Goicoechea de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jth.12615_bb0080","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1111\/jth.12615_bb0085","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/1521-4141(2002010)32:10<2773::AID-IMMU2773>3.0.CO;2-G","article-title":"The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in\u00a0vitro and in\u00a0vivo studies","volume":"32","author":"Marzari","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1111\/jth.12615_bb0090","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria","volume":"373","author":"Parker","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/jth.12615_bb0095","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.transproceed.2012.07.141","article-title":"Tailored eculizumab therapy in the management of complement factor\u00a0H\u2010mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report","volume":"44","author":"Xie","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1111\/jth.12615_bb0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2012.10.044","article-title":"Monitoring and modeling treatment of atypical hemolytic uremic syndrome","volume":"54","author":"Heinen","year":"2013","journal-title":"Mol Immunol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12615","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622040284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622040284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12615\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:08:20Z","timestamp":1761534500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622040284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1538783622040284"],"URL":"https:\/\/doi.org\/10.1111\/jth.12615","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}